泰恩康：CKBA并非2025年诺贝尔医学奖得主的特定研究成果

Core Viewpoint - The company TianKang (301263) clarified that CKBA is not the specific research outcome of the 2025 Nobel Prize in Medicine, but it focuses on the core areas of immunological "immune tolerance" and "immune regulation" [1] Summary by Relevant Categories - Product Development - CKBA is not a broad immunosuppressant but offers a more targeted approach compared to traditional immunosuppressants, providing a new strategy for restoring self-immune balance [1]